← Issue №4/ week of Jul 26, 2026/Endoscopy

Improving follow-up of abnormal stool test results used for colorectal cancer screening.

From GI Signals issue №4: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Endoscopy guideline · Jul 29, 2026 · GIE · IF 8.0

Improving follow-up of abnormal stool test results used for colorectal cancer screening.

Guideline / reviewcolorectal cancer screeninghealth servicescolonoscopyguideline
Clinical takeawayImplement coordinated strategies such as patient navigation, digital tools, and open access colonoscopy to improve follow-up colonoscopy rates after abnormal stool tests.
What it foundFollow-up colonoscopy rates after abnormal stool tests remain suboptimal, with actionable strategies identified to improve adherence.
ContextConfirms the known gap in follow-up colonoscopy after abnormal stool tests and provides evidence-based interventions to address it, aligning with current guidelines emphasizing timely follow-up.
Reinforcessuggested applicable standard· USMSTF 2021 (Patel et al., Gastrointest Endosc 2022;95:1-15) / USPSTF 2021 / ACS 2018

Decision at stakeensuring timely follow-up colonoscopy after positive stool tests

For average-risk adults, colorectal cancer screening is routine from age 45-75 (2021 update lowered the start age from 50 to 45; USPSTF/USMSTF/ACS concordant). The specific USMSTF criterion for stopping in previously well-screened patients is: individuals up to date with screening who have negative prior screening (particularly high-quality colonoscopy) should consider stopping at age 75 OR when life expectancy is less than 10 years, not 5 years.

From our summary of this standard, unedited — the part the paper bears on. marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

For average-risk adults, colorectal cancer screening is routine from age 45-75 (2021 update lowered the start age from 50 to 45; USPSTF/USMSTF/ACS concordant). For ages 76-85, the decision to start or continue is individualized, based on shared decision-making that weighs prior screening history, comorbidity, life expectancy, CRC risk, and patient preference (USPSTF Grade C). Screening is not recommended/offered at age 86 or older. The specific USMSTF criterion for stopping in previously well-screened patients is: individuals up to date with screening who have negative prior screening (particularly high-quality colonoscopy) should consider stopping at age 75 OR when life expectancy is less than 10 years, not 5 years. Individuals without adequate prior screening may be considered for screening up to age 85 depending on age and comorbidities. New alarm symptoms (iron deficiency anemia, GI bleeding, change in bowel habits, weight loss) always warrant workup regardless of age or screening status; this remains sound general practice though it is not a specific guideline citation.

USMSTF 2021 (Patel et al., Gastrointest Endosc 2022;95:1-15) / USPSTF 2021 / ACS 2018 · reviewed 2026-07-19 ↗
Levin TR … Williams KN · Gastrointestinal Endoscopy · IF 8.0 · PubMed ↗Permalink
← Read the whole of issue №4 Every paper GI Signals surfaces gets a page like this one. All issues